drugset
drugset / Trial / NCT06556966

A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects

NCT06556966 ↗

Phase 1 Completed 66 enrolled Luye Pharma Group Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a single-center, randomized, double-blind, placebo-controlled, ascending single oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects.

Timeline

Start
2024-08-19
Primary completion
2025-02-13
Completion
2025-02-13

Drugs

EvaluationDrugModalityDoseRoute
Subject LY03020 Unknown 2.5 mg Oral
Subject LY03020 Unknown 5 mg Oral
Subject LY03020 Unknown 10 mg Oral
Subject LY03020 Unknown 20 mg Oral
Subject LY03020 Unknown 40 mg Oral
Subject LY03020 Unknown 60 mg Oral
Subject LY03020 Unknown 80 mg Oral
Subject LY03020 Unknown 100 mg Oral

Indications

Alzheimer disease schizophrenia